Drug that blocks genetic switch shows promise against aggressive childhood brain cancer

Researchers found that a class of experimental drugs can reprogram how cancer cells burn fuel, potentially offering a new treatment path for medulloblastoma, the most common malignant brain tumor in children. The finding could accelerate development of therapies targeting a genetic driver present in about 30% of cases.

Originaltitel: Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition